semaglutide alcohol use disorder clinical trial alcohol use disorder - GLP1 andalcohol use disorder They also had significantly lower levels of weekly alcohol craving Semaglutide: A Promising Frontier in Alcohol Use Disorder Treatment - Clinical Trial Insights

Eli Lillyalcohol use disorder The journey to effectively treat Alcohol Use Disorder (AUD) is continually evolving, and recent clinical trial research is highlighting the significant potential of semaglutide, a drug primarily known for its roles in diabetes management and weight loss. Emerging evidence suggests that this GLP-1 receptor agonist may offer a novel therapeutic avenue for individuals struggling with alcohol consumption and related challenges. This article delves into the findings of various studies, providing a comprehensive overview of semaglutide's impact on alcohol use disorder.

The Growing Body of Evidence: Clinical Trials Unveiling Semaglutide's Efficacy

A notable clinical trial, a randomized clinical trial, published in *JAMA Psychiatry*, investigated the effects of once-weekly semaglutide in adults diagnosed with Alcohol Use Disorder. This early-Phase II human laboratory trial, employing a randomized, placebo-controlled, dose-ranging design, found that participants receiving semaglutide experienced substantial reductions in their alcohol consumptionClinical Trial on Semaglutide Shows Promise for Treatment .... Specifically, low-dose semaglutide reduced the amount of alcohol consumed during laboratory self-administration tasksOnce-Weekly Semaglutide in Adults With Alcohol Use .... Furthermore, the study indicated a medium effect on reducing alcohol intake.Semaglutide for Alcohol Use Disorder

Another significant trial, referencing the work of Hendershot et al. (2025), assessed the effects of subcutaneous semaglutide on alcohol consumption in adults with Alcohol Use Disorder. The findings from this randomized clinical trial revealed that semaglutide not only reduced overall drinking, but also associated cravingsCU Researcher Studying Effects of GLP-1 Drugs on .... Participants often reported significantly lower levels of weekly alcohol craving throughout the study period. This observation is crucial, as reducing the desire to drink is a key component in managing AUD.2023年11月27日—The paper is titled "Significant Decrease inAlcohol Use DisorderSymptoms Secondary toSemaglutideTherapy for Weight Loss: A Case Series." ...

The USC-led trial confirms side effect that semaglutide, also recognized by brand names like Ozempic and Wegovy, could be beneficial for individuals aiming to decrease their alcohol intake. This aligns with the broader understanding of GLP-1 and alcohol use disorder, suggesting a potential class-wide effect. While semaglutide is a prominent focus, other GLP-1 agonists, such as Exenatide once weekly for alcohol use disorder, have also been investigated in similar randomized, placebo-controlled trials, further solidifying the therapeutic potential of this drug class.2023年11月27日—The paper is titled "Significant Decrease inAlcohol Use DisorderSymptoms Secondary toSemaglutideTherapy for Weight Loss: A Case Series." ...

Quantifying the Impact: Specific Parameters and Verifiable Information

The impact of semaglutide appears to extend beyond general reductions in alcohol consumption. Various studies have highlighted specific quantitative improvements:

* Reduced Drinks Per Drinking Day: Research indicates that semaglutide reduced drinks per drinking day, a critical metric for assessing the severity of drinking patterns2025年2月13日—A once-weekly injection ofsemaglutidecould cut alcohol cravings and reduce the amount someone living withalcohol use disorder(AUD) drinks on some days in a ....

* Decreased Heavy Drinking Days: A significant outcome observed in several trials is the reduction in heavy drinking days, a vital indicator of progress in managing Alcohol Use Disorder.

* Lowered Peak Breath Alcohol Concentration: Studies have shown that semaglutide resulted in lower peak breath alcohol concentrations post-treatment, suggesting a physiological impact on alcohol metabolism or absorption.2025年2月12日—clinical trialsto evaluate GLP-1RAs foralcohol use disorder. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT05520775. JAMA ...

* Reduced Alcohol Cravings: As mentioned, a consistent finding across multiple investigations is the substantial reduction in alcohol cravings.This is anearly-Phase II human laboratory trialusing a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide. This is evidenced by self-report data and potentially by physiological markers.

* Impact on Drinking Frequency: While some studies emphasize reductions in the amount consumed on drinking days, others have explored changes in the proportion of drinking days. Findings here can vary, but the overall trend points towards a beneficial effect on managing alcohol use.

Expert Views and the Future of AUD Treatment

Experts in the field have reacted positively to the emerging data2025年3月28日—A randomizedclinical trialfound that once-weeklysemaglutidereduced the amount ofalcoholconsumed over 9 weeks of treatment.. The sentiment is that this research is among the first controlled trials demonstrating the potential efficacy of GLP-1RAs in humans with Alcohol Use Disorder, building upon promising preclinical findings. The potential for repurposing semaglutide and liraglutide for alcohol use disorder is a significant development, offering hope for more effective and accessible treatment options.

The NCT05520775 identifier points to a specific clinical trial actively investigating semaglutide for Alcohol Use DisorderRepurposing semaglutide to treat alcohol use disorder. These ongoing clinical trials are crucial for further validating these initial findings and understanding the long-term effects and optimal dosing strategies2026年1月1日—One randomized phase 2trialevaluated the effects of weeklysemaglutideonalcohol consumptionand cravings in adults with AUD.7Semaglutide....

While semaglutide is primarily recognized for its role as a weight loss and diabetes drug, its efficacy in addressing alcohol use disorder is an exciting and rapidly developing area of research. The scientific community is keenly watching as more clinical trials report their findings, potentially paving the way for semaglutide to become a cornerstone therapy for individuals seeking to overcome alcohol consumption challenges and achieve lasting recovery. The ongoing exploration into its multifaceted benefits underscores the dynamic nature of medical research and the continuous pursuit of better healthcare solutions.